About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by Regeneron Pharmaceuticals in April 2022. It operates as an oligonucleotides for cancer immunotherapy are developed via innate immune activation. Checkmate Pharmaceuticals has raised $175.08 million across 6 funding rounds from investors including Regeneron Pharmaceuticals, BrightEdge and Longitude Capital. The company has 16 employees. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is CHECKMATE PHARMACEUTICALS, INC. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Founded in 2015 and based in Cambridge, United States, Checkmate Pharmaceuticals operates in the biotechnology sector. Focus is placed on research and development of CpG DNA-based therapies to stimulate the innate immune system against tumors. This approach integrates Toll-like receptor 9 activation with checkpoint inhibitors. The lead candidate, CMP-001, a CpG-A oligonucleotide, is evaluated in combination with pembrolizumab for melanoma treatment in a Phase 1b trial.
- Headquarters Cambridge, United States
- Employees 16
- Stage Public
- SectorsHealthcare
- Website checkmatepharma.com
- Social LinkedIn
- Acquired by Regeneron Pharmaceuticals (Apr 2022)
- Legal Name Checkmate Pharmaceuticals, Inc.
- Total Equity Funding$175.08M (USD)
in 6 rounds
- Latest Funding Round$85.08M (USD), Series C
Jun 2020
- InvestorsRegeneron Pharmaceuticals
& 10 more
- Employee Count16
- Acquired byRegeneron Pharmaceuticals
(Apr 2022)
Funding Insights of Checkmate Pharmaceuticals
Checkmate Pharmaceuticals has successfully raised a total of $175.08M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $85.08 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $175.08M
- Total Rounds 6
- Last Round Series C — $85.08M
- First Round $25M
(Feb 2017)
- Investors Count 10
All 6 funding rounds of Checkmate Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $85.08M | Series C | – | Longitude Capital, Novo Holdings | |
| Apr 2020 | $10M | Debt – Conventional | – | – | – |
| Jan 2020 | $16M | Series B | – | – | – |
| Mar 2019 | $22M | Series B | – | Decheng Capital | |
| Jun 2017 | $27M | Series B | – | F-Prime Capital | |
| Feb 2017 | $25M | Series A | – | – |
11 investors in total: 11 institutional.
Investors in Checkmate Pharmaceuticals
Checkmate Pharmaceuticals has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, BrightEdge and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life science sector | – | longitudecapital.com | Menlo Park, United States | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Early-stage life science focused VC firm investing in geographies such as Europe and the US | – | medicxi.com | London, United Kingdom | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China | |
Search engine optimization tools for enterprises are provided. | 2007 | brightedge.com | San Mateo, United States |
Investor details for Checkmate Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Checkmate Pharmaceuticals
959 people are tracked at Checkmate Pharmaceuticals (452 in leadership, 3 in board & advisors, 504 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Nanita Cranford | Vice President, Global Regulatory Operations | Leadership |
Kris Sprague | Global Head, Program And Project Planning | Leadership |
Danielle Clemente | Director HR Business Partner | Leadership |
Leslie Cascone Rohrbacker | Executive Director Human Resources | Leadership |
Barbara Forster | Senior Director, Global Benefits | Leadership |
Jeanne O'Connell | Director QC Technical Resources | Leadership |
George D. Yancopoulos | President & Chief Scientific Officer | Leadership |
Leonard S. Schleifer | Founder, President & CEO | Leadership |
Priscila Gonçalves | Senior Medical Director | Leadership |
Janie Parrino | Global Program Head, Immunology, Inflammation, And Infectious Diseases | Leadership |
Nicole Dossin | Senior Director, Development Program Management (ces And Precision Medicine) | Leadership |
Paulina Olivo Weber | Director, Development Operations And Portfolio Management | Leadership |
Dana Pipkin | National Account Director | Leadership |
Gina Thomas | Vice President Talent Acquisition | Leadership |
Humberto Lara-Guerra | Senior Medical Director Clinical Sciences | Leadership |
Yvette Payne | Director Hematology Field Medical Team | Leadership |
Srinivasan Sadanandhamurthy | Senior Director, Data Engineering | Leadership |
Frank Loganzo | Director, Solution Partner, Research & Preclinical Development IT | Leadership |
Colleen Scott | Director, Talent Management | Leadership |
Naveen Karumuri | Associate Director, AI Engineering. | Leadership |
939 more people are available in the full profile.
Complete people profiles for Checkmate Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Checkmate Pharmaceuticals
5 dated milestones of Checkmate Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Checkmate Pharmaceuticals is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series C, of $85.1M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Regeneron Pharmaceuticals.
Competitors of Checkmate Pharmaceuticals
Checkmate Pharmaceuticals has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Checkmate Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Checkmate Pharmaceuticals (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Checkmate Pharmaceuticals
Complete news archive for Checkmate Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Checkmate Pharmaceuticals
Checkmate Pharmaceuticals was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Checkmate Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Checkmate Pharmaceuticals is a funded company, having raised a total of $175.08M across 6 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Feb 2017.
Checkmate Pharmaceuticals has 16 employees.
Founded in 2015 and based in Cambridge, United States, Checkmate Pharmaceuticals operates in the biotechnology sector. Focus is placed on research and development of CpG DNA-based therapies to stimulate the innate immune system against tumors. This approach integrates Toll-like receptor 9 activation with checkpoint inhibitors. The lead candidate, CMP-001, a CpG-A oligonucleotide, is evaluated in combination with pembrolizumab for melanoma treatment in a Phase 1b trial.
Checkmate Pharmaceuticals's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Checkmate Pharmaceuticals has 11 investors. Key investors include Regeneron Pharmaceuticals, BrightEdge, Longitude Capital, Novo Holdings, and Medicxi.
Checkmate Pharmaceuticals operates through Checkmate Pharmaceuticals, Inc..
Yes. Checkmate Pharmaceuticals was acquired by Regeneron Pharmaceuticals in April 2022.